Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates

Financial Performance - Arcturus Therapeutics reported a quarterly loss of $0.49 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.25, representing an earnings surprise of +60.80% [1] - The company posted revenues of $17.15 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 50.63%, although this is a decline from $41.67 million in the same quarter last year [2] - Over the last four quarters, Arcturus has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Arcturus Therapeutics shares have declined approximately 48.6% since the beginning of the year, contrasting with the S&P 500's gain of 14.4% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.49 on revenues of $9.77 million, and for the current fiscal year, it is -$3.49 on revenues of $73.55 million [7] - The earnings outlook and estimate revisions will be crucial for assessing the stock's future performance [4][5] Industry Context - The Medical - Biomedical and Genetics industry, to which Arcturus belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The performance of Arcturus may also be influenced by the overall industry trends and the performance of peer companies, such as TScan Therapeutics, which is expected to report a quarterly loss of $0.35 per share [9]